Cargando…
Apatinib is effective for treatment of advanced hepatocellular carcinoma
As treatment options for hepatocellular carcinoma (HCC) are currently limited, we evaluated the efficacy and safety of oral apatinib, a VEGFR-2 inhibitor, on patients with advanced HCC. Twenty-two patients from Tianjin Medical University Cancer Institute and Hospital were enrolled for evaluation. Ap...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739662/ https://www.ncbi.nlm.nih.gov/pubmed/29285275 http://dx.doi.org/10.18632/oncotarget.22337 |
_version_ | 1783287909698240512 |
---|---|
author | Kong, Yinlong Sun, Lin Hou, Zhenyu Zhang, Yongqiang Chen, Ping Cui, Yunlong Zhu, Xiaolin Song, Tianqiang Li, Qiang Li, Huikai Zhang, Ti Qin, Lunxiu |
author_facet | Kong, Yinlong Sun, Lin Hou, Zhenyu Zhang, Yongqiang Chen, Ping Cui, Yunlong Zhu, Xiaolin Song, Tianqiang Li, Qiang Li, Huikai Zhang, Ti Qin, Lunxiu |
author_sort | Kong, Yinlong |
collection | PubMed |
description | As treatment options for hepatocellular carcinoma (HCC) are currently limited, we evaluated the efficacy and safety of oral apatinib, a VEGFR-2 inhibitor, on patients with advanced HCC. Twenty-two patients from Tianjin Medical University Cancer Institute and Hospital were enrolled for evaluation. Apatinib was administered at 500 mg/day or 250 mg/day continuously. Clinical endpoints were time to disease progression (TTP), overall survival (OS), and safety. The median TTP of treated patients was 10.4 months (95% CI 3.4 -17.5). At the last follow-up, 50% patients had survived longer than 11.4 months from the first dose. Complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) rates were 0%, 40.9%, 40.9%, and 18.2%, respectively. The most common apatinib-related adverse events were hand-foot skin reaction (HFSR) (81.8%) and diarrhea (77.3%). Hypertension (27.3%) and HFSR (13.6%) were the most frequent grade 3/4 adverse events. In summary, results of this small study indicate that apatinib is well tolerated and extremely effective for the treatment of advanced HCC. It is therefore imperative to design and carry out well-controlled clinical trials to confirm its efficacy. |
format | Online Article Text |
id | pubmed-5739662 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-57396622017-12-28 Apatinib is effective for treatment of advanced hepatocellular carcinoma Kong, Yinlong Sun, Lin Hou, Zhenyu Zhang, Yongqiang Chen, Ping Cui, Yunlong Zhu, Xiaolin Song, Tianqiang Li, Qiang Li, Huikai Zhang, Ti Qin, Lunxiu Oncotarget Research Paper As treatment options for hepatocellular carcinoma (HCC) are currently limited, we evaluated the efficacy and safety of oral apatinib, a VEGFR-2 inhibitor, on patients with advanced HCC. Twenty-two patients from Tianjin Medical University Cancer Institute and Hospital were enrolled for evaluation. Apatinib was administered at 500 mg/day or 250 mg/day continuously. Clinical endpoints were time to disease progression (TTP), overall survival (OS), and safety. The median TTP of treated patients was 10.4 months (95% CI 3.4 -17.5). At the last follow-up, 50% patients had survived longer than 11.4 months from the first dose. Complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) rates were 0%, 40.9%, 40.9%, and 18.2%, respectively. The most common apatinib-related adverse events were hand-foot skin reaction (HFSR) (81.8%) and diarrhea (77.3%). Hypertension (27.3%) and HFSR (13.6%) were the most frequent grade 3/4 adverse events. In summary, results of this small study indicate that apatinib is well tolerated and extremely effective for the treatment of advanced HCC. It is therefore imperative to design and carry out well-controlled clinical trials to confirm its efficacy. Impact Journals LLC 2017-11-06 /pmc/articles/PMC5739662/ /pubmed/29285275 http://dx.doi.org/10.18632/oncotarget.22337 Text en Copyright: © 2017 Kong et al. http://creativecommons.org/licenses/by/3.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) (CC-BY), which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Research Paper Kong, Yinlong Sun, Lin Hou, Zhenyu Zhang, Yongqiang Chen, Ping Cui, Yunlong Zhu, Xiaolin Song, Tianqiang Li, Qiang Li, Huikai Zhang, Ti Qin, Lunxiu Apatinib is effective for treatment of advanced hepatocellular carcinoma |
title | Apatinib is effective for treatment of advanced hepatocellular carcinoma |
title_full | Apatinib is effective for treatment of advanced hepatocellular carcinoma |
title_fullStr | Apatinib is effective for treatment of advanced hepatocellular carcinoma |
title_full_unstemmed | Apatinib is effective for treatment of advanced hepatocellular carcinoma |
title_short | Apatinib is effective for treatment of advanced hepatocellular carcinoma |
title_sort | apatinib is effective for treatment of advanced hepatocellular carcinoma |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739662/ https://www.ncbi.nlm.nih.gov/pubmed/29285275 http://dx.doi.org/10.18632/oncotarget.22337 |
work_keys_str_mv | AT kongyinlong apatinibiseffectivefortreatmentofadvancedhepatocellularcarcinoma AT sunlin apatinibiseffectivefortreatmentofadvancedhepatocellularcarcinoma AT houzhenyu apatinibiseffectivefortreatmentofadvancedhepatocellularcarcinoma AT zhangyongqiang apatinibiseffectivefortreatmentofadvancedhepatocellularcarcinoma AT chenping apatinibiseffectivefortreatmentofadvancedhepatocellularcarcinoma AT cuiyunlong apatinibiseffectivefortreatmentofadvancedhepatocellularcarcinoma AT zhuxiaolin apatinibiseffectivefortreatmentofadvancedhepatocellularcarcinoma AT songtianqiang apatinibiseffectivefortreatmentofadvancedhepatocellularcarcinoma AT liqiang apatinibiseffectivefortreatmentofadvancedhepatocellularcarcinoma AT lihuikai apatinibiseffectivefortreatmentofadvancedhepatocellularcarcinoma AT zhangti apatinibiseffectivefortreatmentofadvancedhepatocellularcarcinoma AT qinlunxiu apatinibiseffectivefortreatmentofadvancedhepatocellularcarcinoma |